Method for preparing dihydronaphthalene derivative
A novel method addressing the inefficiencies of the conventional process for producing dihydronaphthalene derivative compound (I) involves specific reaction and purification steps, resulting in a cost-effective, high-yield, and efficient industrial-scale production process.
Patent Information
- Application Number
- PCT/CN2024/136971
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-06
- Filing Date
- 2024-12-05
- Publication Date
- 2025-06-12
AI Technical Summary
The conventional method for preparing the dihydronaphthalene derivative compound (I) is not suitable for industrial-scale production due to high costs, long production times, and low yields, particularly in the step of preparing methyl 1-[[3S)-3-methyl-6-(4,4,4-trifluorobutoxy)-3,4-dihydronaphthalen-2-yl]methyl]azetidine-3-carboxylate from (3S)-6-hydroxy-3-methyl-3,4-dihydronaphthalene-2-carbaldehyde.
A method involving specific reaction conditions, including enol esterification, methylation, asymmetric hydrogen transfer, deprotection, cyclization, hydride reduction, formylation, and crystallization steps, is developed to efficiently prepare high-purity compound (I) using ethyl 4-(3-methoxyphenyl)-3-oxobutanoate as a raw material and a high-purity compound (II) as an intermediate, thereby ensuring safe and efficient operation on an industrial scale.
The method significantly reduces production costs by about 90%, shortens the preparation time by approximately 58%, and enhances the total yield from the starting materials to the final compound (I) by about 9-fold, making it feasible to produce high-purity compound (I) efficiently and economically on an industrial scale.
Smart Images

Figure CN2024136971_12062025_PF_FP_ABST
Abstract
Description
METHOD FOR PREPARING DIHYDRONAPHTHALENE DERIVATIVETECHNICAL FIELDThe present disclosure relates to a method for preparing a dihydronaphthalene derivative. More specifically, the present invention relates to a method for preparing 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylic acid mono-4-hydroxybenzoate (hereinafter, may be abbreviated as compound (I) ) . The present disclosure also generally relates to an intermediate useful for the above method.BACKGROUND ARTSphingosine-1-phosphate [ (2S, 3R, 4E) -2-amino-3-hydroxyoctadec-4-enyl-1-phosphate; hereinafter occasionally abbreviated as S1P] is a lipid which is synthesized by metabolic turnover of sphingolipids in cells and by the extracellular action of a secreted sphingosine kinase. It is proposed that sphingosine-1-phosphate acts as an intercellular communication mediator as well as an intracellular second messenger.Among S1P receptors, with regard to S1P5 (EDG-8) receptor, it is known that S1P5 (EDG-8) receptor is highly expressed in oligodendrocytes (oligodendroglia) and oligodendrocyte progenitor cells. It is revealed that S1P5 receptor promotes the induction of differentiation of oligodendrocyte progenitor cells to oligodendrocytes when S1P5 receptor is activated (see Non Patent Literatures 1 and 2) . Oligodendrocytes are a kind of glial cells which form the myelin sheaths (myelin) by binding to the axons of nerve cells. Accordingly, it is considered that a compound which has an agonist activity of S1P5 receptor is useful for treating neurodegenerative disease or demyelinating disease such as multiple sclerosis because the compound promotes the regeneration of myelin which has disappeared (demyelination) in nerve cells.In addition, it is known that S1P5 receptor is highly expressed also in natural killer (NK) cells and it is revealed that the migration of NK cells is induced by the activation of S1P5 receptor (see Non Patent Literature 3) .Further, S1P5 receptor is highly expressed in patrolling monocytes which are known to be involved in the tumor immunity, and therefore, there is a possibility that the activation of the tumor immunity is induced by the activation of S1P5 receptor (see Non Patent Literatures 4 and 5) .Patent Literature 1 states that 1- [ [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalene-2-yl] methyl] azetidine-3-carboxylic acid (hereinafter, may be abbreviated as compound A) activates the S1P5 receptor and is useful for treating neurodegenerative diseases, autoimmune diseases, infectious diseases, or cancers.Patent Literature 2 states that a plurality of salts containing 4-hydroxybenzoate of the compound A are excellent in chemical stability among various acid addition salts of the compound A, and thus are useful for treatment of S1P5-mediated diseases, for example, neurodegenerative diseases, autoimmune diseases, infectious diseases, or cancers.In providing the compound A or the compound (I) , various production methods have been investigated.For example, Example 10 described in Patent Literature 2 describes a method for preparing the compound (I) (hereinafter, may be abbreviated as a conventional production method) . In the conventional production method, (3S) -6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde as a production intermediate (hereinafter, may be abbreviated as compound (II) , and the structural formula of compound (II) is described below) was obtained from racemic 6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde by high performance liquid chromatography using a chiral column. In addition, in order to obtain a high-purity compound (I) , purification by column chromatography was required in each production step. Therefore, it is considered that the conventional production method is not suitable for preparing the high-purity compound (I) on an industrial production scale, and there is such an object that it takes a lot of cost and a long production period to prepare the high-purity compound (I) by the conventional preparation method. Further, the conventional preparing method has a problem in that the yield of the step of preparing methyl 1- [ [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalene-2-yl] methyl] azetidine-3-carboxylate from (3S) -6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde is low. In addition, there have been included operations that are not suitable for preparation on an industrial preparation scale for safety concerns. Therefore, it has been considered that the conventional preparation method is not suitable for preparing the high-purity compound (I) on an industrial preparation scale.CITATIONS LISTSPatent LiteraturesPatent Literature 1: WO 2019 / 163917 APatent Literature 2: WO 2021 / 033729 ANon Patent LiteratureNon Patent Literature 1: The Journal of Neuroscience, Vol. 25, No. 6, pages 1459 -1469, 2005Non Patent Literature 2: The FASEB Journal, Vol. 21, pages 01503 -1514, 2007Non Patent Literature 3: Nature Immunology, Vol. 8, No. 12, pages 1337 -1344, 2007Non Patent Literature 4: European Journal of Immunology, Vol. 43, pages 1667 -1675, 2013Non Patent Literature 5: Science, Vol. 350, No. 6263, pages 985 -990, 2015SUMMARY OF INVENTIONTECHNICAL PROBLEMSAn object of the present invention is to provide a method for preparing a compound (I) , the method being suitable for an industrial preparation scale.SOLUTIONS TO PROBLEMSFor the purpose of preparing a high-purity compound (I) on an industrial preparation scale, there is a need for a method for preparing the high-purity compound (I) at low cost with high yield. As a result of intensive investigations, the inventors of the present invention have found, in order to solve the above object, reaction conditions under which a geometric isomer of a double bond can be controlled and a preparation method for obtaining a desired isomer in a process for preparing the compound (II) . In addition, in each preparation step, reaction conditions for obtaining a high-purity intermediate or the compound (I) , post-treatment conditions for removing impurities, and crystallization conditions have been found. Further, a method for preparing the compound (I) , the method allowing safe operation even at an industrial preparation scale has been found.That is, the present disclosure provides, for example, the following embodiments.[1] A method for preparing a compound (I) :the method comprising:a step (A) of using an electrophile, anda compound represented by formula (1) :[wherein R1 and R2 each independently represent a C1 to C6 alkyl group or a benzyl group]and performing an enol esterification reaction to provide a compound represented by formula (2) :[wherein R6 representsan arrow represents a bonding position with an oxygen atom, and other symbols represent the same meaning as described above] ;a step (B) of using a methyl metal reagent and the compound represented by formula (2) and performing a methylation reaction to provide a compound represented by formula (3) :[wherein all symbols represent the same meaning as described above] ; anda step (C) of using the compound represented by formula (3) and performing an asymmetric hydrogen transfer reaction to provide a compound represented by formula (4) :[wherein a symbolrepresents bonding to a front side of a paper surface (that is, β disposition) , and other symbols represent the same meaning as described above] .[2] The method for preparing a compound (I) according to [1] , further comprising:a step (D) of using the compound represented by formula (4) and performing a deprotection reaction to provide a compound represented by formula (5) :[wherein all symbols represent the same meaning as in [1] ] or a salt thereof;a step (E) of using a carboxyl group activating agent and the compound represented by formula (5) or a salt thereof and performing a cyclization reaction to provide a compound represented by formula (6) :[wherein a symbolrepresents bonding to an opposite side of the paper surface (that is, αdisposition) , and other symbols represent the same meaning as in [1] ] ;a step (F) of using the compound represented by formula (6) and performing a hydride reduction reaction to provide a compound represented by formula (7) :[wherein a symbolrepresents an α disposition, a β disposition, or a mixture of any ratio thereof, and other symbols represent the same meaning as in [1] and described above] ;a step (G) of using a formylating agent and the compound represented by formula (7) and performing a formylation reaction to provide a compound represented by formula (8) :[wherein all symbols represent the same meaning as in [1] and described above] ; anda step (H) of using the compound represented by formula (8) and performing a deprotection reaction to provide a compound (II) :[wherein all symbols represent the same meaning as in [1] and described above] .[3] The method for preparing a compound (I) according to [1] or [2] , wherein the enol esterification reaction in the step (A) is an enol esterification reaction with an electrophile, an alkali metal salt, a base, and the compound represented by formula (1) .[3-1] The method for preparing a compound (I) according to [3] , wherein the electrophile in the step (A) is p-toluenesulfonyl chloride, the alkali metal salt is lithium chloride, and the base is N, N, N', N'-tetramethylethane-1, 2-diamine.[4] The method for preparing a compound (I) according to [1] or [2] , wherein the methylation reaction in the step (B) is a methylation reaction with a methyl metal reagent, an additive, a metal catalyst, and the compound represented by formula (2) .[4-1] The method for preparing a compound (I) according to [4] , wherein the methyl metal reagent in the step (B) is methylmagnesium chloride, the additive is zinc chloride, and the metal catalyst is bis (triphenylphosphine) palladium (II) dichloride.[5] The method for preparing a compound (I) according to [1] or [2] , wherein the asymmetric hydrogen transfer reaction in the step (C) is an asymmetric hydrogen transfer reaction with a ligand, a metal, a reducing agent, and the compound represented by formula (3) .[6] The method for preparing a compound (I) according to [5] , wherein the ligand in the step (C) is (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl di-tert-butylphosphine, the metal is copper (II) acetate monohydrate, and the reducing agent is triethoxysilane.[7] The method for preparing a compound (I) according to [2] , wherein the deprotection reaction in the step (D) is a deprotection reaction with a base and the compound represented by formula (4) .[7-1] The method for preparing a compound (I) according to [7] , wherein the base in the step (D) is sodium hydroxide.[8] The method for preparing a compound (I) according to [2] , wherein the carboxyl group activating agent in the step (E) is an acid anhydride.[8-1] The method for preparing a compound (I) according to [8] , wherein the acid anhydride in the step (E) is trifluoroacetic anhydride.[8-2] The method for preparing a compound (I) according to [2] , wherein the hydride reduction reaction in the step (F) is a hydride reduction reaction with a reducing agent and the compound represented by formula (6) .[8-3] The method for preparing a compound (I) according to [8-2] , wherein the reducing agent in the step (F) is sodium borohydride.[8-4] The method for preparing a compound (I) according to [2] , wherein the formylating agent in the step (G) is a combination of N, N-dimethylformamide and phosphorus oxychloride.[9] The method for preparing a compound (I) according to [2] , wherein the deprotection reaction in the step (H) is a deprotection reaction with an acid, a base, and the compound represented by formula (8) .[9-1] The method for preparing a compound (I) according to [9] , wherein the acid in the step (H) is 1-dodecanethiol, and the base is sodium tert-butoxide.[9-2] The method for preparing a compound (I) according to [2] , wherein the deprotection reaction in the step (H) is a deprotection reaction with a Lewis acid.
[0010] The method for preparing a compound (I) according to [2] , further comprising:a step (K) of using the compound (II) and a compound represented by formula (9) :[wherein R4 represents chlorine, bromine, iodine,and an arrow represents a bonding position with a carbon atom] and performing a nucleophilic substitution reaction to provide a compound (III) :wherein all symbols represent the same meaning as in [1] or [2] ;a step (M) of using the compound (III) and a compound represented by formula (10) :[wherein R3 represents a C1 to C6 alkyl group or a benzyl group] and performing a reductive amination reaction to provide a compound represented by formula (11) :wherein all symbols represent the same meaning as in [1] or [2] and described above; anda step (P) of using the compound represented by formula (11) in the presence of 4-hydroxybenzoic acid and performing a deprotection reaction and adduct formation to provide a compound represented by formula (12) :[wherein Y represents a number of 0 to 5 and other symbols represent the same meaning as in [1] or [2] ] .
[0011] The method for preparing a compound (I) according to
[0010] , wherein the nucleophilic substitution reaction in the step (K) is a nucleophilic substitution reaction with a base, the compound represented by formula (9) , and the compound (II) .[11-1] The method for preparing a compound (I) according to
[0011] , wherein the base in the step (K) is potassium carbonate, and the compound represented by formula (9) is 4-bromo-1, 1, 1-trifluorobutane.
[0012] The method for preparing a compound (I) according to
[0010] , wherein the reductive amination reaction in the step (M) is a reductive amination reaction with a reducing agent, an acid, the compound represented by formula (10) , and the compound (III) .[12-1] The method for preparing a compound (I) according to
[0012] , wherein the reducing agent in the step (M) is sodium borohydride, the acid is propionic acid, and the compound represented by formula (10) is methyl azetidine-3-carboxylate hydrochloride.
[0013] The method for preparing a compound (I) according to
[0010] , wherein the deprotection reaction in the step (P) is a deprotection reaction with a base.[13-1] The method for preparing a compound (I) according to
[0013] , wherein the base in the step (P) is sodium hydroxide.
[0014] The method for preparing a compound (I) according to
[0010] , further comprising:a step (R) of using a compound represented by formula (12) in the presence or absence of 4-hydroxybenzoic acid and performing crystal polymorph transition to provide the compound (I) .[14-1] The method for preparing a compound (I) according to
[0010] , further comprising:a step (R) of using 4-hydroxybenzoic acid and a compound represented by formula (12) and performing crystal polymorph transition to provide the compound (I) .
[0015] Ethyl (2Z) -4- (3-methoxyphenyl) -3- [ (4-methylbenzene-1-sulfonyl) oxy] but-2-enoate.[15-1] The method for preparing a compound (I) according to [1] or [2] , and
[0010] , wherein the step (A) includes a crystallization step for increasing purity of the compound represented by formula (2) .[15-2] The method for preparing a compound (I) according to [2] or
[0010] , wherein the step (E) includes a crystallization step for increasing purity of the compound represented by formula (6) .[15-3] The method for preparing a compound (I) according to [2] or
[0010] , wherein the step (G) includes a crystallization step for increasing purity of the compound represented by formula (8) .[15-4] The method for preparing a compound (I) according to [2] or
[0010] , further comprising a crystallization step for increasing purity of the compound (II) in the step (H) .[15-5] The method for preparing a compound (I) according to
[0010] , further comprising a crystallization step for increasing purity of the compound (III) in the step (K) .[15-6] The method for preparing a compound (I) according to
[0010] , wherein the step (M) includes a crystallization step for increasing purity of the compound represented by formula (11) .[15-7] The method for preparing a compound (I) according to
[0010] , wherein the step (P) includes a crystallization step for increasing purity of the compound represented by formula (12) .[15-8] The method for preparing a compound (I) according to
[0014] , further comprising a crystallization step for increasing purity of the compound (I) in the step (R) .[15-9] Use of ethyl (2Z) -4- (3-methoxyphenyl) -3- [ (4-methylbenzene-1-sulfonyl) oxy] but-2-enoate as an intermediate in the step (B) according to [1] .[15-10] Ethyl (2Z) -4- (3-methoxyphenyl) -3- [ (4-methylbenzene-1-sulfonyl) oxy] but-2-enoate, which is an intermediate used in the step (B) according to [1] .ADVANTAGEOUS EFFECTS OF INVENTIONThe present disclosure provides a method for efficiently preparing a high-purity compound (I) at low cost by using ethyl 4- (3-methoxyphenyl) -3-oxobutanoate (CAS registry number: 324570-26-5) as a raw material and using a high-purity compound (II) as a preparation intermediate.DESCRIPTION OF EMBODIMENTSHereinafter, the present invention will be described in detail.Unless specifically defined otherwise, the terms used herein have the meanings as commonly understood by one of ordinary skill in the art of organic chemistry, medicine, pharmacy, molecular biology, microbiology, and the like. The following describes definitions for some of the terms used herein, which supersede the general understanding herein.As used herein, the following terms have the meanings set forth below.The singular forms “a” , “an” , and “the” include plural referents unless the context clearly dictates otherwise.As used herein, the term “or” is a disjunction (that is, and / or) and does not indicate an exclusive disjunction unless explicitly indicated by the terms “either” , “otherwise” , “alternatively” , and words of similar effect.The term “C1 to C6 alkyl” as used herein refers to a group derived from a linear or branched saturated hydrocarbon containing 1 to 6 carbon atoms. Examples of the C1 to C6 alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2, 2-dimethylpropyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2, 2-dimethylbutyl, 2, 3-dimethylbutyl, 1-methyl-1-ethylpropyl, 2-methyl-2-ethylpropyl, 1-ethylbutyl, and 2-ethylbutyl.Examples of the electrophile as used herein include, but are not limited to, para-toluenesulfonyl (p-toluenesulfonyl) chloride, methanesulfonyl chloride, benzenesulfonyl chloride, 3-nitrobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, and diphenyl phosphorochlorinate.Examples of the reducing agent of the following Reaction 1-3, as used herein, include, but are not limited to, trimethylsilane, triethylsilane, trimethoxysilane, triethoxysilane, dimethylphenylsilane, triphenylsilane, and poly (methylhydrosiloxane) .Examples of the reducing of the following Reaction 2-1, as used herein, include, but are not limited to, sodium borohydride, lithium borohydride, sodium cyanoborohydride, 2-methylpyridine borane, sodium triacetoxyborohydride, lithium aluminum hydride, isobutylaluminum hydride, borane, triethylsilane, and sodium bis (2-methoxyethoxy) aluminum hydride.Examples of the reducing agent of the following Reaction 3-2, as used herein, include, but are not limited to, sodium borohydride, lithium borohydride, sodium cyanoborohydride, 2-methylpyridine borane, and sodium triacetoxyborohydride.Examples of the ligand used herein include, but are not limited to, (R) -1- [ (Sp) -R2- (diphenylphosphino) ferrocenyl] ethyl di-tert-butylphosphine, (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl dicyclohexylphosphine, (R) -1- [ (Sp) -2- (dicyclohexylphosphino) ferrocenyl] ethyl di-tert-butylphosphine, (R) -1- [ (Sp) -2- (dicyclohexylphosphino) ferrocenyl] ethyl dicyclohexylphosphine, (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl diphenylphosphine, (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl di (3, 5-xylyl) phosphine, or a ligand having a configuration different from these.Examples of the dehydrating chlorinating agent as used herein include, but are not limited to, phosphorus oxychloride and thionyl chloride.Examples of the Lewis acid as used herein include, but are not limited to, boron tribromide, aluminum chloride, and hydrobromic acid.Examples of the nucleophile as used herein include, but are not limited to, N, N-dimethylformamide, and N-methylformanilide.Examples of the formylating agent, as used herein, includes combinations of dehydrating chlorinating agent and nucleophiles.Examples of the inorganic salt as used herein include, but are not limited to, ammonium chloride and sodium chloride.Examples of the alkali metal salt as used herein include, but are not limited to, lithium chloride, lithium bromide, and lithium iodide.Examples of the methyl metal reagent used herein include, but are not limited to, methylmagnesium chloride, methylmagnesium bromide, methylmagnesium iodide, and methyllithium.Examples of the carboxyl group activating agent used herein includes an acid anhydride and an acid halide agent, and the carboxyl group activating agent is preferably the acid anhydride.Examples of the acid anhydride as used herein include, but are not limited to, acetic anhydride, trifluoroacetic anhydride, and phthalic anhydride.Examples of the acid halide agent used herein include, but are not limited to, thionyl chloride, phosphorus oxychloride, and oxalyl chloride.Examples of the metal catalyst used herein include, but are not limited to, bis (triphenylphosphine) palladium (II) dichloride, tetrakis (triphenylphosphine) palladium.The adduct, as used herein, refers to a new chemical species (AB) resulting from the direct bonding (addition) of two different molecules (A) and (B) in a form in which the nature of the bonding is changed, but neither molecule has atoms increased or decreased. The adduct includes a salt and a cocrystal.The deprotection reaction as used herein is a reaction for removing a protecting group, and includes a hydrolysis reaction and a demethylation reaction.As used herein, unless otherwise specified, symbols are used as would be apparent to one of ordinary skill in the art.represents bonding to the front side of the paper surface (that is, β disposition) , andrepresents bonding to the opposite side of the paper surface (that is, α disposition) , andrepresents an α disposition, a β disposition, or a mixture in any ratio thereof.R1 is preferably methyl or ethyl. R1 is more preferably methyl.R2 is preferably methyl or ethyl. R2 is more preferably ethyl.R3 is preferably methyl or ethyl. R3 is more preferably methyl.R4 is preferably chlorine, bromine, or iodine. R4 is more preferably bromine.R5 is preferably methyl or ethyl. R5 is more preferably methyl.R6 is preferablyThe reaction disclosed in the present specification may be performed by a batch process (also referred to as batch production or batch manufacturing) performed by a procedure of charging a reactant into a reactor, performing a reaction and a post-treatment, and collecting a product, or may be performed by a flow process (also referred to as continuous flow production or continuous flow manufacturing) that is a method of continuously charging a reactant from one side of a reactor and continuously collecting a product from the other side.The following synthetic schemes illustrate how the compounds of the present disclosure can be prepared. These schemes are exemplary and are not intended to limit possible techniques in the art that can be used to prepare the compounds disclosed herein. The starting materials shown within these schemes can be obtained from commercial sources or can be prepared by well-established methods known to those skilled in the art.[In reaction scheme 1, all symbols represent the same meaning as described above. ]Reaction 1-1 is an enol esterification reaction (refer to Chem. Eur. J. 2015, 21, 5934-5945) , and can be performed, for example, by performing the reaction at -50 to 100℃ in an organic solvent (toluene, dimethyl sulfoxide, N, N-dimethylacetamide, N, N-dimethylformamide, 1, 3-dimethyl-2-imidazolidinone, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, acetonitrile, and the like, but not limited thereto) in the presence or absence of an alkali metal salt (lithium chloride, lithium bromide, lithium iodide, and the like, but not limited thereto) , in the presence or absence of a base (N, N, N', N'-tetramethylethane-1, 2-diamine, N, N'-dimethylpropyleneurea, hexamethylphosphoric acid triamide, and the like, but not limited thereto) , and in the presence of an electrophile (para-toluenesulfonyl chloride, methanesulfonyl chloride, benzenesulfonyl chloride, 3-nitrobenzenesulfonyl chloride, 4-nitrobenzenesulfonyl chloride, diphenyl phosphorochlorinate, and the like, but not limited thereto) . Crystallization may be performed to obtain a high-purity compound. Crystallization can be performed by stirring the reaction solution at -20 to 60℃ in the presence or absence of a solvent (methanol, ethanol, isopropanol, acetonitrile, and the like, but not limited thereto) and in the presence or absence of water.The compound represented by formula (2) can be prepared by performing the enol esterification reaction described above with the compound represented by formula (1) .Reaction 1-2 is a methylation reaction (refer to J. Chem. Soc. Chem. Commun. 1977, 683-684) , and can be performed by performing the reaction at -20 to 100℃ in the presence or absence of a solvent (dimethyl sulfoxide, N, N-dimethylacetamide, N, N-dimethylformamide, 1, 3-dimethyl-2-imidazolidinone, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, and the like, but not limited thereto) , in the presence or absence of an additive (zinc chloride, aluminum chloride, and the like, but not limited thereto) , in the presence of a methyl metal reagent (methylmagnesium chloride, methylmagnesium bromide, methylmagnesium iodide, methyllithium, and the like, but not limited thereto) , in the presence or absence of a metal catalyst (bis (triphenylphosphine) palladium (II) dichloride, tetrakis (triphenylphosphine) palladium, and the like, but not limited thereto) .The compound represented by formula (3) can be prepared by performing the methylation reaction described above with the compound represented by formula (2) .Reaction 1-3 is an asymmetric hydrogen transfer reaction (refer to Angew. Chem. Int. Ed. 1988, 27, 1180-1181) , and can be performed by performing the reaction at -100 to 150℃ in the presence or absence of a solvent (toluene, dimethyl sulfoxide, N, N-dimethylacetamide, N, N-dimethylformamide, 1, 3-dimethyl-2-imidazolidinone, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, and the like, but not limited thereto) , in the presence or absence of a solvent (methanol, ethanol, isopropanol, tert-butanol, triphenylmethanol, dimethylphenylcarbinol, and the like, but not limited thereto) , in the presence or absence of water, in the presence of a ligand ( (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl di-tert-butylphosphine, (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl dicyclohexylphosphine, (R) -1- [ (Sp) -2- (dicyclohexylphosphino) ferrocenyl] ethyl di-tert-butylphosphine, (R) -1- [ (Sp) -2- (dicyclohexylphosphino) ferrocenyl] ethyl dicyclohexylphosphine, (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl diphenylphosphine, (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl di (3, 5-xylyl) phosphine, and the like, but not limited thereto) , in the presence of a metal (copper (I) chloride, copper (II) chloride, copper (I) bromide, copper (II) bromide, copper (I) iodide, copper (II) iodide, copper (I) acetate, copper (II) acetate, copper (I) acetate monohydrate, copper (II) acetate monohydrate, and the like, but not limited thereto) , and in the presence of a reducing agent (trimethylsilane, triethylsilane, trimethoxysilane, triethoxysilane, dimethylphenylsilane, triphenylsilane, poly (methylhydrosiloxane, and the like, but not limited thereto) .The compound represented by formula (4) can be prepared by performing the asymmetric hydrogen transfer reaction described above with the compound represented by formula (3) .Reaction 1-4 is a deprotection reaction, and can be performed, for example, by performing the reaction at -20 to 100℃ in an organic solvent (1, 2-dimethoxyethane, methanol, ethanol, isopropanol, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, acetonitrile, N, N-dimethylformamide, and the like, but not limited thereto) in the presence of a base (lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, cesium carbonate, and the like, but not limited thereto) .The compound represented by formula (5) can be prepared by performing the deprotection reaction described above with the compound represented by formula (4) .Reaction 1-5 is a cyclization reaction (refer to J. Org. Chem 1985, 50, 705-707) , and can be performed by performing the reaction at -20 to 100℃ in an organic solvent (chlorobenzene, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, acetonitrile, and the like, but not limited thereto) in the presence or absence of a carboxyl group activating agent (the carboxyl group activating agent includes acid anhydrides and acid halide agents) . Crystallization may be performed to obtain a high-purity compound. Crystallization can be performed by stirring at 0 to 60℃ in the presence or absence of a base (lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, cesium carbonate, and the like, but not limited thereto) and in the presence of water. Purification may be performed to obtain a high-purity compound. The purification can be performed by stirring at -10 to 60℃ in the presence or absence of a solvent (methanol, ethanol, isopropanol, and the like, but not limited thereto) and in the presence or absence of water.The compound represented by formula (6) can be prepared by performing the cyclization reaction described above with the compound represented by formula (5) .[In reaction scheme 2, all symbols represent the same meaning as described above. ]Reaction 2-1 is a hydride reduction reaction (refer to J. Am. Chem. Soc. 1953, 75, 192-195) , and can be performed, for example, by performing the reaction at -50 to 100℃ in an organic solvent (chlorobenzene, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, acetonitrile, methanol, and the like, but not limited thereto) in the presence of a reducing agent (sodium borohydride, lithium borohydride, sodium cyanoborohydride, 2-methylpyridine borane, sodium triacetoxyborohydride, lithium aluminum hydride, isobutyl aluminum hydride, borane, triethylsilane, sodium bis (2-methoxyethoxy) aluminum hydride, and the like, but not limited thereto) , and in the presence or absence of an acid (acetic acid, propionic acid, and the like, but not limited thereto) .The compound represented by formula (7) can be prepared by performing the hydride reduction reaction described above with the compound represented by formula (6) .Reaction 2-2 is a formylation reaction, and is performed by, for example, reacting at -20 to 100℃ in an organic solvent (ethyl acetate, isopropyl acetate, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, and the like, but not limited thereto) , in the presence of a nucleophile (N, N-dimethylformamide, N-methylformanilide, and the like, but not limited thereto) , and in the presence of a dehydrating chlorinating agent (phosphorus oxychloride, thionyl chloride, and the like, but not limited thereto) . Crystallization may be performed to obtain a high-purity compound. Crystallization can be performed by stirring the reaction solution at -20 to 60℃ in the presence or absence of a solvent (n-heptane, n-hexane, and the like, but not limited thereto) .The compound represented by formula (8) can be prepared by performing the formylation reaction described above with the compound represented by formula (7) .Reaction 2-3 is a deprotection reaction, and when R1 is a methyl group, a demethylation reaction (refer to Tetrahedron Lett. 1970, 16, 1327-1328) can be performed. The demethylation reaction can be performed, for example, by performing the reaction at 0 to 200℃ in an organic solvent (dimethyl sulfoxide, N, N-dimethylacetamide, N, N-dimethylformamide, 1, 3-dimethyl-2-imidazolidinone, and the like, but not limited thereto) , in the presence or absence of a Lewis acid (boron tribromide, aluminum chloride, hydrobromic acid, and the like, but not limited thereto) , in the presence or absence of an acid (ethanethiol, 1-dodecanethiol, and the like, but not limited thereto) , and in the presence or absence of a base (lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, and the like, but not limited thereto) . Crystallization may be performed to obtain a high-purity compound. Crystallization can be performed by stirring the reaction solution at -20 to 60℃ in the presence or absence of a solvent (methanol, ethanol, isopropanol, diethyl ether, methyl t-butyl ether, cyclopentyl methyl ether, and the like, but not limited thereto) and in the presence or absence of a solvent (n-heptane, n-hexane, and the like, but not limited thereto) .The compound (II) can be prepared by performing the demethylation reaction described above with the compound represented by formula (8) .[In reaction scheme 3, all symbols represent the same meaning as described above. ]Reaction 3-1 is a nucleophilic substitution reaction (refer to Liebigs Ann. Chem. 1851, 77, 37-49) , and can be performed, for example, by performing the reaction at -20 to 200℃ in an organic solvent (N-methylpyrrolidone, chlorobenzene, dimethyl sulfoxide, N, N-dimethylacetamide, N, N-dimethylformamide, 1, 3-dimethyl-2-imidazolidinone, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, and the like, but not limited thereto) , in the presence of an electrophile (4-chloro-1, 1, 1-trifluorobutane, 4-bromo-1, 1, 1-trifluorobutane, 4-iodo-1, 1, 1-trifluorobutane, 4, 4, 4-trifluorobutyl methanesulfonate, 4, 4, 4-trifluorobutyl benzenesulfonate, 4, 4, 4-trifluorobutyl p-toluenesulfonate, 4, 4, 4-trifluorobutyl 4-nitrobenzenesulfonate, 3-nitrobenzenesulfonate, diphenyl 4, 4, 4-trifluorobutyl phosphate, and the like, but not limited thereto) , in the presence or absence of a base (lithium hydroxide, sodium hydride, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, triethylamine, N, N-diisopropylethylamine, pyridine, and the like, but not limited thereto) , and in the presence or absence of water. Crystallization may be performed to obtain a high-purity compound. Crystallization can be performed by stirring the reaction solution at 0 to 60℃ in the presence or absence of a solvent (methanol, ethanol, isopropanol, and the like, but not limited thereto) and in the presence or absence of water.The compound (III) can be prepared by the nucleophilic substitution reaction described above with the compound (II) and the compound represented by formula (9) .Reaction 3-2 is a reductive amination reaction (refer to J. Am. Chem. Soc. 1971, 93, 2897-2904) , and can be performed, for example, by performing the reaction at -50 to 100℃ in an organic solvent (chlorobenzene, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, acetonitrile, and the like) , in the presence of azetidine ester (methyl azetidine-3-carboxylate, ethyl azetidine-3-carboxylate, isopropyl azetidine-3-carboxylate, benzyl azetidine-3-carboxylate, and the like, but not limited thereto) , in the presence of a reducing agent (sodium borohydride, lithium borohydride, sodium cyanoborohydride, 2-methylpyridine borane, sodium triacetoxyborohydride, and the like, but not limited thereto) , in the presence or absence of an acid (acetic acid, propionic acid, and the like, but not limited thereto) , and in the presence or absence of a base (triethylamine, N, N-diisopropylethylamine, pyridine, and the like, but not limited thereto) . Extraction may be performed to obtain a high-purity compound. The extraction can be performed by stirring the reaction solution in the presence of a solvent (methyl t-butyl ether, cyclopentyl methyl ether, 2-methyltetrahydrofuran, and the like, but not limited thereto) , in the presence or absence of a base (sodium carbonate, potassium carbonate, cesium carbonate, and the like, but not limited thereto) , in the presence or absence of an inorganic salt (ammonium chloride, sodium chloride, and the like, but not limited thereto) , and in the presence of water. Crystallization may be performed to obtain a high-purity compound. Crystallization can be performed by collecting the organic layer, concentrating the organic layer, and then stirring at -10 to 60℃ in the presence or absence of a solvent (methanol, ethanol, and isopropanol, and the like, but not limited thereto) and in the presence or absence of water.The compound represented by formula (11) can be prepared by performing the reductive amination reaction described above with the compound (III) and the compound represented by formula (10) .Reaction 3-3 is a deprotection reaction and adduct formation. The deprotection reaction can be performed, for example, by performing the reaction at -20 to 100℃ in an organic solvent (methanol, ethanol, isopropanol, diethyl ether, tetrahydrofuran, methyl t-butyl ether, cyclopentyl methyl ether, acetonitrile, N, N-dimethylformamide, and the like, but not limited thereto) and in the presence of a base (lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, cesium carbonate, and the like, but not limited thereto) . The adduct formation can be performed by reacting at -20 to 100℃ in an organic solvent (methanol, ethanol, isopropanol, and the like, but not limited thereto) and in the presence of 4-hydroxybenzoic acid and water. Crystallization may be performed to obtain a high-purity compound. Crystallization can be performed by stirring the reaction solution at 0 to 60℃ in the presence or absence of a solvent (methanol, ethanol, isopropanol, and the like, but not limited thereto) and in the presence or absence of water.The compound represented by formula (12) can be prepared by performing the deprotection reaction and the adduct formation with the compound represented by formula (11) .The crystal polymorph transition can be performed, for example, by stirring at -20 to 100℃ in the presence or absence of an organic solvent (acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone, dichloromethane, dichloroethane, chloroform, methyl acetate, ethyl acetate, isopropyl acetate, methanol, ethanol, n-propanol, isopropanol, diethyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, n-hexane, n-heptane, and the like, or mixed solvents thereof, but are not limited thereto) , or in a mixed solvent of organic solvents (acetonitrile, acetone, methyl ethyl ketone, methyl isobutyl ketone, dichloromethane, dichloroethane, chloroform, methyl acetate, ethyl acetate, isopropyl acetate, methanol, ethanol, n-propanol, isopropanol, diethyl ether, diisopropyl ether, tetrahydrofuran, 2-methyltetrahydrofuran, n-hexane, n-heptane, and the like, but not limited thereto) , in the presence or absence of water, or in a mixed solvent of an organic solvent (methanol, ethanol, n-propanol, and isopropanol) and water, and in the presence or absence of 4-hydroxybenzoic acid.The compound (I) can be prepared by performing the crystal polymorph transition described above with the compound represented by formula (12) .In each of the reaction process formulas, the compound represented by formula (1) , the compound represented by formula (9) and the compound represented by formula (10) , which are used as raw materials, are known or can be easily prepared by known methods.All literatures cited herein are hereby incorporated by reference.The above description is all non-limiting, and the present invention is defined in the appended claims, and various modifications are possible without departing from the technical idea thereof. Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these examples.EXAMPLESHereinafter, the present disclosure will be described in detail by Examples, but the present disclosure is not limited thereto.Conditions used in HPLC analysis in the following Examples are shown below.Condition AColumn: XBridge C 18, 4.6 mm ID x 150 mm, 3.5 μm; Flow rate: 1.0 mL / min; Temperature: 25℃; Mobile phase A: 10 mmol / L KH2PO4 aqueous solution (pH 3.0, H3PO4) ; Mobile phase B: acetonitrile: gradient (ratio of mobile phase A: mobile phase B is described) : 0 to 18 min (70: 30 to 20: 80) , 18 to 30 min (20: 80) .Condition BColumn: XBridge C 18, 4.6 mm ID x 150 mm, 3.5 μm; Flow rate: 1.0 mL / min; Temperature: 25℃; Mobile phase A: 10 mmol / L KH2PO4 aqueous solution (pH 3.0, H3PO4) ; Mobile phase B: acetonitrile: gradient (ratio of mobile phase A: mobile phase B is described) : 0 to 18 min (70: 30 to 20: 80) , 18 to 50 min (20: 80) .Condition CColumn: YMC-Pack C8, 4.6 mm ID × 150 mm, 3.0 μm; Flow rate: 1.0 mL / min; Temperature: 25℃; Mobile phase A: 10 mmol / L KH2PO4 aqueous solution (pH 2.8, H3PO4) ; Mobile phase B: acetonitrile: gradient (ratio of mobile phase A: mobile phase B is described) : 0 to 60 min (85: 15 to 62.5: 37.5) , 60 to 85 min (62.5: 37.5 to 20: 80) , 85 to 95 min (20: 80) .The solvent used for the measurement is shown in parentheses in the NMR section.The compound names used in the present specification are named using a computer program ACD / Name (registered trademark) provided by Advanced Chemistry Development, which generally performs naming according to the IUPAC regulations, or according to the IUPAC nomenclature.Abbreviations used in the following schemes and Examples are well known to those skilled in the art.Example 1: Ethyl (2Z) -4- (3-methoxyphenyl) -3- [ (4-methylbenzene-1-sulfonyl) oxy] but-2-enoateUnder a nitrogen atmosphere, a mixture of ethyl 4- (3-methoxyphenyl) -3-oxobutanoate (140 g) (CAS registry number: 324570-26-5) , acetonitrile (420 mL) , and toluene (70 g) was stirred at 15 to 35℃ for 30 minutes, and lithium chloride (37.7 g) was added thereto. The mixture was cooled to -25 to -15℃ and N, N, N', N'-tetramethylethane-1, 2-diamine (82.6 g) was added at -25 to -15℃ and stirred for 1.5 hours. A solution of p-toluenesulfonyl chloride (135.6 g) in acetonitrile (560 mL) was added to the mixture at -25 to -15℃ over 1.5 hours, and the mixture was stirred for 1 hour. Isopropanol (420 mL) was added at -25 to -5℃ over 15 minutes, then the temperature was raised to -5 to 5℃, and water (980 mL) was added dropwise at -5 to 5℃, and then the mixture was stirred for 1 hour. The obtained solid was filtered and washed with acetonitrile / water (1 / 3, 280 mL) . Acetonitrile / water (1 / 3, 520 mL) was added to the obtained solid, and the mixture was stirred at 20 to 30℃ for 2 hours. The obtained solid was filtered and washed with acetonitrile / water (1 / 3, 280 mL) . The obtained solid was dried under a reduced pressure at 55℃ or less to provide the title compound (219.5 g) .1H-NMR (CDCl3) δ 7.89, 7.34, 7.21, 6.80, 6.73, 6.66, 5.40, 4.03, 3.78, 3.62, 2.45, 1.19;HPLC retention time (min) : 17.5 (Condition A) .Example 2: Ethyl (2E) -4- (3-methoxyphenyl) -3-methylbut-2-enoateUnder a nitrogen atmosphere, a mixture of tetrahydrofuran (400 mL) and zinc chloride (19.2 g) was stirred, the temperature was cooled to -5℃, 3.0 mol / L methylmagnesium chloride tetrahydrofuran solution (89.6 mL) was added dropwise at -5 to 15℃ over 3 hours, and the mixture was stirred for 1 hour. The compound prepared in Example 1 (50.0 g) was added to the mixture, then bis (triphenylphosphine) palladium (II) dichloride (89.8 mg) was added thereto, and the mixture was heated to 25℃ and stirred for 6 hours. Toluene (300 mL) and 1.0 mol / L hydrochloric acid (440 mL) were added to another reaction reactor, and the mixture was stirred at 25℃. To this solution, the reaction solution was added dropwise at 20 to 30℃, the mixture was stirred for 1 hour, and then the organic layer was separated. The organic layer was washed sequentially with water (440 mL) , a 1%N-acetylcysteine aqueous solution (500 mL) , a 10%sodium sulfide aqueous solution (500 mL) , and a 10%sodium chloride aqueous solution (500 mL) , then the organic layer was filtered through a filter, and the filtrate was concentrated under a reduced pressure at 55℃ or less. The mixture was concentrated until the total amount of the concentrated solution reached 150 mL, then toluene (250 mL) was added thereto, and the mixture was concentrated under a reduced pressure at 55℃ until the amount of the concentrated solution reached 150 mL. Toluene (250 mL) was added, and the mixture was concentrated under a reduced pressure until the amount of the concentrated solution reached 150 mL to prepare a concentrated solution of the title compound.HPLC retention time (min) : 16.3 (Condition A) .Example 3: Ethyl (3S) -4- (3-methoxyphenyl) -3-methylbutanoateUnder a nitrogen atmosphere, toluene (175 mL) and tert-butanol (18.9 g) were stirred for 1 hour, and (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl di-tert-butylphosphine (1.39 g) and copper (II) acetate monohydrate (0.51 g) were added thereto. The mixture was heated to 40℃ and stirred for 3 hours. To this solution, the concentrated solution prepared in Example 2 and purified water (1.0 mL) were added, triethoxysilane (70.9 mL) was added dropwise at 35℃ to 45℃ over 2 hours, and then the mixture was stirred for 4 hours. The reaction solution was cooled to 25℃, a 3 mol / L aqueous sodium hydroxide solution (150 mL) was added thereto at 20 to 30℃, and the mixture was stirred for 1 hour. The reaction solution was concentrated under a reduced pressure at 55℃ until the amount of the reaction solution reached 150 mL to provide a concentrated solution of the title compound.HPLC retention time (min) : 16.6 (Condition A) .Example 4: (3S) -4‐ (3‐methoxyphenyl) -3‐methylbutanoic acidUnder a nitrogen atmosphere, 1, 2-dimethoxyethane (150 mL) and a 3 mol / L aqueous sodium hydroxide solution (150 mL) were added to the concentrated solution prepared in Example 3, and the mixture was stirred, heated to 60℃, and stirred for 6 hours. The reaction solution was cooled to 25℃, and the aqueous layer was removed. n-Heptane (250 mL) was added to the organic layer, and the mixture was stirred for 30 minutes to remove the organic layer. n-Heptane (250 mL) was added to the aqueous layer again, and the mixture was stirred for 30 minutes to remove the organic layer. At 10 to 30℃, 3 mol / L hydrochloric acid (65 mL) was added to the aqueous layer to adjust the pH to 1 to 2. Methyl-tert-butyl ether (250 mL) was added to the aqueous layer, and the mixture was stirred for 20 minutes to separate the organic layer. Methyl-tert-butyl ether (250 mL) was added to the aqueous layer, and the mixture was stirred for 30 minutes to separate the organic layer. The organic layers were combined, filtered, and concentrated under a reduced pressure at 50℃ until the total amount of the filtrate reached 100 mL. Acetonitrile (250 mL) was added, and the mixture was concentrated under a reduced pressure at 50℃ until the total amount of the filtrate reached 100 mL. Acetonitrile (250 mL) was added thereto, and the mixture was concentrated under a reduced pressure at 50℃ until the total amount of the filtrate reached 100 mL to provide a concentrated solution of the title compound.HPLC retention time (min) : 8.6 (Condition A) .Example 5: (3S) -6-methoxy-3-methyl-3, 4-dihydronaphthalen-1 (2H) -oneUnder a nitrogen atmosphere, acetonitrile (12.5 mL) was added to the concentrated solution prepared in Example 4 at 25℃, stirring was started, and the mixture was cooled to 0℃. To this solution, a solution prepared by adding acetonitrile (87.5 mL) and trifluoroacetic anhydride (26.9 g) at 20℃ under a nitrogen atmosphere in another reactor was added dropwise at -5 to 5℃. Thereafter, the temperature was raised to 10℃, and the mixture was stirred for 2 hours. This solution was added to a solution prepared by adding a 1 mol / L aqueous sodium hydroxide solution at 19 to 25℃under a nitrogen atmosphere in another reactor, and the suspension was stirred at 20 to 25℃ for 12 hours. The solid was collected by filtration and washed with purified water (100 mL) . The obtained wet crystals were dried under a reduced pressure at 40℃ or less. Under a nitrogen atmosphere, isopropanol (150 mL) was added to the obtained solid, and the mixture was heated to 45℃ to prepare a solution. The solution was cooled to 35℃ and purified water (150 mL) was added dropwise at 30 to 40℃ over 30 min and stirred for 30 min. Purified water (300 mL) was added dropwise at 30 to 40℃ over 1 hour, and the mixture was stirred for 1 hour. Thereafter, the suspension was cooled to 20 to 25℃ and stirred for 3 hours. The solid was collected by filtration and washed with a mixed solution of isopropanol (25 mL) and purified water (75 mL) . The obtained solid was dried under a reduced pressure at 40℃ or less to provide the title compound (17.0 g) .1H-NMR (CDCl3) δ 7.80, 6.82, 6.69, 3.86, 2.98 to 2.88, 2.76 to 2.60, 2.40 to 2.21, 1.13;HPLC retention time (min) : 9.8 (Condition A) .Example 6: (3S) -6-methoxy-3-methyl-1, 2, 3, 4-tetrahydronaphthalene-1-olUnder a nitrogen atmosphere, tetrahydrofuran (140 mL) and the compound prepared in Example 5 (CAS registry number: 1809905-75-6) (40.0 g) were stirred at 15℃ to prepare a solution. In another reactor, under a nitrogen atmosphere, methanol (40 mL) was added dropwise to a mixture of tetrahydrofuran (140 mL) and sodium borohydride (8.8 g) at 10 to 20℃ with stirring, and then the mixture was stirred for 30 minutes. The prepared solution was added dropwise thereto at 10 to 20℃, and the mixture was stirred for 6 hours. In another reactor, a mixture of a 15%ammonium chloride aqueous solution (400 mL) and methyl-tert-butyl ether (280 mL) was cooled to 0℃ under a nitrogen atmosphere, and the reaction solution was added dropwise at -5 to 5℃. Thereafter, the mixture was stirred at 25℃ for 30 minutes, and then the aqueous layer was removed. A 10%sodium chloride aqueous solution (200 mL) was added to the organic layer, the mixture was stirred for 30 minutes, and then the aqueous layer was removed. The mixture was concentrated under a reduced pressure at 45℃ until the volume of the organic layer reached 140 mL. Isopropyl acetate (280 mL) was added thereto, and the mixture was concentrated under a reduced pressure at 45℃ until the volume of the organic layer reached 140 mL. Isopropyl acetate (280 mL) was added thereto, and the mixture was concentrated under a reduced pressure at 45℃ until the volume of the organic layer reached 140 mL. Isopropyl acetate (280 mL) was added thereto, and the mixture was concentrated under a reduced pressure at 45℃ until the volume of the organic layer reached 260 mL to provide a concentrated solution of the title compound.HPLC retention time (min) : 8.0 (Condition A) .Example 7: (3S) -6-methoxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehydeUnder a nitrogen atmosphere, the concentrated solution prepared in Example 6 was stirred at 25℃, N, N-dimethylformamide (46.1 g) was added thereto, and the mixture was cooled to 2.5℃. Phosphorus oxychloride (95.7 g) and isopropyl acetate (20 mL) were added at -4℃ to 10℃, the mixture was heated to 60℃ and stirred for 6 hours, and then the reaction solution was cooled to 25℃. In another reactor, a 3 mol / L sodium hydroxide solution (840 mL) was added under a nitrogen atmosphere, the mixture was stirred at 0℃, and the reaction solution was added dropwise at -5℃ to 5℃. The mixture was heated to 25℃ and stirred for 30 minutes, and then the aqueous layer was removed. A 10%sodium chloride aqueous solution (280 mL) was added to the organic layer, the mixture was stirred for 30 minutes, and then the aqueous layer was removed. The organic layer was filtered, and concentrated under a reduced pressure at 45℃ until the volume of the filtrate reached 120 mL. Isopropyl alcohol (280 mL) was added to the concentrated solution, and the mixture was concentrated under a reduced pressure at 45℃ until the volume of the concentrate reached 120 mL. Isopropyl alcohol (280 mL) was added to the concentrated solution again, and the mixture was concentrated under a reduced pressure at 45℃ until the volume of the concentrate reached 120 mL. Isopropyl alcohol (280 mL) was added to the concentrated solution, the mixture was concentrated under a reduced pressure at 45℃ until the volume of the concentrate reached 200 mL, and cooled to 30℃. Purified water (200 mL) was added dropwise over 1 hour, and the mixture was stirred at 30℃ for 30 minutes. Purified water (400 mL) was added dropwise to the suspension over 2 hours, cooled to 20℃, and stirred for 2 hours. The solid was collected by filtration and washed with a mixed solution of isopropanol (20 mL) and purified water (60 mL) . The obtained solid was dried under a reduced pressure at 45℃ or less to provide the title compound (34.9 g) .1H-NMR (CDCl3) δ 9.57, 7.26 to 7.20, 7.16, 6.81 to 6.74, 6.76, 3.85, 3.12 to 3.00, 2.64, 0.94;HPLC retention time (min) : 11.1 (Condition A) .Example 8: (3S) -6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehydeUnder a nitrogen atmosphere, a mixture of 1, 3-dimethyl-2-imidazolidinone (270 mL) and the compound (90.0 g) prepared in Example 7 was stirred at 25℃ to prepare a solution. In another reactor, under a nitrogen atmosphere, a mixture of 1, 3-dimethyl-2-imidazolidinone (315 mL) and sodium-tert-butoxide (64.1 g) was stirred and heated to 90℃. Thereafter, 1-dodecanethiol (225.1 g) was added, and the mixture was stirred for 30 minutes. The prepared solution was added dropwise thereto over 1 hour and stirred at 90℃ for 6 hours. The reaction solution was cooled to 25℃, purified water (1080 mL) was added dropwise over 1 hour, and then the mixture was stirred for 20 minutes. Methyl-tert-butyl ether (540 mL) was added to the solution, the mixture was stirred at 25℃ for 20 minutes, and then the organic layer was removed. Methyl-tert-butyl ether (540 mL) was added to the aqueous layer, the mixture was stirred at 25℃ for 20 minutes, and then the organic layer was removed. The aqueous layers were combined, and 4 mol / L hydrochloric acid (270 mL) was added thereto to adjust the pH of the reaction solution to adjust the pH to be less than 2. Methyl-tert-butyl ether (1080 mL) was added to this solution, the mixture was stirred at 25℃ for 20 minutes, and then an aqueous layer was separated. Methyl-tert-butyl ether (540 mL) was added to the aqueous layer, the mixture was stirred at 25℃ for 20 minutes, and then the aqueous layer was removed. The organic layers were combined, a 10%sodium chloride aqueous solution (900 mL) was added thereto, the mixture was stirred for 15 minutes, and then the aqueous layer was removed. A 10%sodium chloride aqueous solution (900 mL) was added to the organic layer again, the mixture was stirred for 15 minutes, and then the aqueous layer was removed. Purified water (900 mL) was added to the organic layer, the mixture was stirred for 15 minutes, and then the aqueous layer was removed. The organic layer was filtered, and then concentrated under a reduced pressure at 45℃ until the volume of the filtrate reached 450 mL. n-Heptane (540 mL) was added, and the concentrated solution was concentrated under a reduced pressure at 45℃ until the volume of the concentrated solution reached 450 mL. This operation was further repeated twice. The suspension was cooled to 25℃ and stirred for 1 hour. The solid was collected by filtration and washed with n-heptane (180 mL) to obtain (3S) -6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde including n-heptane.In another reactor, under a nitrogen atmosphere, a mixture of methyl-tert-butyl ether (237 mL) , (3S) -6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde including n-heptane (79.0 g) , and isopropanol (23.7 mL) was heated to 50℃ and stirred for 0.5 hours to form a solution. This solution was cooled to 40℃, seed crystals (79 mg) of (3S) -6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde prepared separately were added thereto, and the mixture was stirred for 1 hour. The suspension was cooled to 30℃ and stirred for 1 hour, n-heptane (395 mL) was added dropwise over 2 hours, and then the mixture was stirred for 1 hour. Thereafter, n-heptane (2370 mL) was added dropwise over 2 hours, and the mixture was stirred for 2 hours and cooled to 0℃. After stirring at 0℃ for 2 hours, the solid was collected by filtration and washed with a mixed solution of methyl-tert-butyl ether (19.8 mL) and n-heptane (138.3 mL) . The obtained solid was dried under a reduced pressure at 45℃ or less to provide the title compound (35.7 g) .Herein, the seed crystals of (3S) -6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde separately prepared were obtained by the method described in Example 3 (1) in the specification of WO 2021 / 033729 A.HPLC retention time (min) : 6.3 (Condition B) .Example 9: (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalene-2-carbaldehydeUnder a nitrogen atmosphere, a mixture of N-methylpyrrolidone (40 mL) , purified water (0.5 mL) , the compound prepared in Example 8 (10.0 g) , 4-bromo-1, 1, 1-trifluorobutane (CAS registry number: 406-81-5) (10.7 g) , and potassium carbonate (8.8 g) was stirred, heated to 60℃ over 1 hour, and stirred for 3 hours. The temperature was cooled to 25℃, and the mixture was stirred for 30 minutes. The suspension was filtered, isopropanol (60 mL) was added to the filtrate under a nitrogen atmosphere, and purified water (30 mL) was added dropwise thereto at 20℃ over 15 minutes. Thereafter, purified water (70 mL) was added dropwise over 30 minutes, and the mixture was stirred for 1 hour. The solid was collected by filtration and washed with a mixed solution of isopropanol (19 mL) and purified water (31 mL) . The obtained solid was dried under a reduced pressure at 50℃ or less to provide the title compound (14.9 g) .HPLC retention time (min) : 18.5 (Condition A) .Example 10: Methyl 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylateA mixture of NaBH4 (3.29 g) and tetrahydrofuran (50 mL) was stirred under a nitrogen atmosphere and cooled to 0℃. Propionic acid (20.3 g) was added at -5℃ to 20℃, and the mixture was stirred at 25℃ for 1 hour and 30 minutes to prepare a solution of a reducing agent. In another reactor, under a nitrogen atmosphere, a mixture of the compound prepared in Example 9 (20.0 g) and acetonitrile (70 mL) was cooled to -10℃. Diisopropylethylamine (4.33 g) and methyl azetidine-3-carboxylate monohydrochloride (CAS registry number: 100202-39-9) (12.2 g) were added and the suspension was stirred for 1 hour. The solution of the reducing agent prepared was added dropwise to the suspension over 1 hour, then the temperature was raised to 25℃, and the mixture was stirred for 2 hours. To this solution, methyl tert-butyl ether (100 mL) and a 5%sodium carbonate aqueous solution (200 mL) were added, the mixture was stirred for 20 minutes, and then the aqueous layer was removed. A 5%aqueous sodium carbonate solution (100 mL) was added to the organic layer, the mixture was stirred for 20 minutes, and then the aqueous layer was removed. A 5%aqueous sodium carbonate solution (100 mL) was added to the organic layer again, the mixture was stirred for 20 minutes, and then the aqueous layer was removed. A 10%ammonium chloride aqueous solution (100 mL) was added to the organic layer, and the mixture was stirred for 20 minutes, then the aqueous layer was removed. A 5%sodium chloride aqueous solution was added to the organic layer, the mixture was stirred for 20 minutes, and then the aqueous layer was removed. Methanol (200 mL) was added to the organic layer, and the mixture was concentrated under a reduced pressure at 40℃ until the volume of the solution reached 100 mL. This operation was repeated twice. Methanol (60 mL) was added to adjust the volume of the solution to 160 mL. The solution was cooled to 2.5℃, seed crystals (10.0 mg) of methyl 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylate prepared separately were added, and the mixture was stirred for 2 hours. Thereafter, a mixed solution of methanol (40 mL) and purified water (100 mL) was added dropwise over 1 hour, and the mixture was stirred for 1 hour. The solid was collected by filtration and washed with a mixed solution of methanol (40 mL) and purified water (40 mL) . The obtained solid was dried under a reduced pressure at 45℃ or less to provide the title compound (24.8 g) .Herein, the seed crystals of methyl 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylate separately prepared were obtained by the method described in Example 5 in the specification of WO 2021 / 033729 A.HPLC retention time (min) : 11.3 (Condition A) .Example 11: 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylic acid mono-4-hydroxybenzoate mono-hydrate (Form C)Under a nitrogen atmosphere, a mixture of the compound (6.0 g) prepared in Example 10 and isopropyl alcohol (18 mL) was stirred, 2 mol / L aqueous sodium hydroxide solution (18 mL) was added dropwise at 10 to 35℃, and then the mixture was stirred at 25℃ for 1 hour. 1 mol / L hydrochloric acid (37.8 mL) was added dropwise at 10 to 35℃, and then the mixture was stirred at 25℃ for 15 minutes. In another reactor, isopropyl alcohol (15 mL) , water (15 mL) , 1 mol / L aqueous sodium hydroxide solution (1.2 mL) , and 4-hydroxybenzoic acid (2.5 g) were added and stirred to prepare a solution. This solution was added to the reaction solution, seed crystals (1.2 mg) of 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylic acid mono-4-hydroxybenzoate mono-hydrate (Form C) prepared separately were added, and then the mixture was stirred at 25℃ for 2 hours. Purified water (102 mL) was added dropwise over 3 hours, and then the mixture was stirred for 3 hours. The precipitated solid was collected by filtration and washed with a mixed solution of isopropyl alcohol (3.0 mL) and purified water (27 mL) . The obtained solid was dried under a reduced pressure at 45℃ or less to provide the title compound (7.4 g) .Herein, the seed crystals of 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylic acid mono-4-hydroxybenzoate mono-hydrate separately prepared were obtained by the method described in Example 12 in the specification of WO 2021 / 033729 A.HPLC retention time (min) : 52.7 (Condition C) .Example 12: 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylic acid mono-4-hydroxybenzoate (Form A)Under a nitrogen atmosphere, a mixture of the compound prepared in Example 11 (145.9 g) , acetone (145.9 mL) , purified water (73.0 mL) , and 4-hydroxybenzoic acid (9.6 g) was stirred to prepare a solution. This solution was heated to 40℃, acetonitrile (1196 mL) and seed crystals (292 mg) of 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylic acid mono-4-hydroxybenzoate (Form A) separately prepared were added, and then the mixture was stirred for 24 hours. The suspension was cooled to 10℃ over 5 hours (cooling rate: 6℃ / h) and then stirred for 12 hours. The precipitated solid was collected by filtration and washed with acetonitrile (438 mL) . The obtained solid was dried under a reduced pressure at 55℃ or less to provide the title compound (131.3 g) .Herein, the seed crystals of 1- { [ (3S) -3-methyl-6- (4, 4, 4-trifluorobutoxy) -3, 4-dihydronaphthalen-2-yl] methyl} azetidine-3-carboxylic acid mono-4-hydroxybenzoate (Form A) separately prepared were obtained by the method described in Example 10 in the specification of WO 2021 / 033729 A.1H-NMR (CD3OD) δ7.86, 7.04, 6.80, 6.75 to 6.71, 6.53, 4.36 to 4.13, 4.03, 3.99, 3.86, 3.47 to 3.39, 3.01, 2.63, 2.43 to 2.28, 2.05 to 1.95, 0.93;HPLC retention time (min) : 52.7 (Condition C) .It should be understood that items in the detailed description are intended to be used to interpret the claims. The SUMMARY OF INVENTION and ABSTRACT sections may set forth one or more, but not all, exemplary embodiments of the disclosure contemplated by the inventor (s) , and are therefore not intended to limit the disclosure and the appended claims in any way.In the conventional preparation method, the compound (II) was obtained from racemic 6-hydroxy-3-methyl-3, 4-dihydronaphthalene-2-carbaldehyde by high performance liquid chromatography using a chiral column, but by the preparation method described in the above Examples, the high-purity compound (II) can be obtained without using the chiral column. In the conventional preparation method, purification by column chromatography is required in each preparation step in order to obtain the high-purity compound (I) , but by the preparation method described in the above Examples, an intermediate including the high-purity compound (II) or compound (I) can be obtained without performing the purification operation. By the preparation method described in the above Examples, reducing the cost of the column, the reagent, the solvent, and the like necessary for preparation can reduce the preparation cost at an industrial preparation scale by about 90%. By the preparation method described in the above Examples, the period for preparing the compound (I) from the starting material on an industrial preparation scale can be shortened by about 58%. By the preparation method described in the above Examples, the total yield from the starting materials to the preparation of the compound (I) can be improved by about-9 fold. Therefore, by the preparation method described in the above Examples, the high-purity compound (I) can be obtained at low cost, with high efficiency, and with high yield.INDUSTRIAL APPLICABILITYBy the preparation method of the present invention, a high-purity compound (I) can be prepared at low cost and efficiently by using ethyl 4- (3-methoxyphenyl) -3-oxobutanoate (CAS registry number: 324570-26-5) as a raw material and using a high-purity compound (II) as a preparation intermediate.
Claims
1.A method for preparing a compound (I) : the method comprising:a step (A) of using an electrophile, anda compound represented by formula (1) :wherein R1 and R2 each independently represent a C1 to C6 alkyl group or a benzyl group,and performing an enol esterification reaction to provide a compound represented by formula (2) :wherein R6 representsan arrow represents a bonding position with an oxygen atom, and other symbols represent the same meaning as described above;a step (B) of using a methyl metal reagent and the compound represented by formula (2) and performing a methylation reaction to provide a compound represented by formula (3) :wherein all symbols represent the same meaning as described above; anda step (C) of using the compound represented by formula (3) and performing an asymmetric hydrogen transfer reaction to provide a compound represented by formula (4) :wherein a symbolrepresents bonding to a front side of a paper surface (that is, β disposition) , and other symbols represent the same meaning as described above.2.The method for preparing a compound (I) according to claim 1, further comprising:a step (D) of using the compound represented by formula (4) and performing a deprotection reaction to provide a compound represented by formula (5) :wherein all symbols represent the same meaning as in claim 1 or a salt thereof;a step (E) of using a carboxyl group activating agent and the compound represented by formula (5) or a salt thereof and performing a cyclization reaction to provide a compound represented by formula (6) :wherein a symbolrepresents bonding to an opposite side of the paper surface (that is, αdisposition) , and other symbols represent the same meaning as in claim 1;a step (F) of using the compound represented by formula (6) and performing a hydride reduction reaction to provide a compound represented by formula (7) :wherein a symbolrepresents an α disposition, a β disposition, or a mixture of any ratio thereof, and other symbols represent the same meaning as in claim 1 and described above;a step (G) of using a formylating agent and the compound represented by formula (7) and performing a formylation reaction to provide a compound represented by formula (8) :wherein all symbols represent the same meaning as in claim 1 and described above; anda step (H) of using the compound represented by formula (8) and performing a deprotection reaction to provide a compound (II) :wherein all symbols represent the same meaning as in claim 1 and described above.3.The method for preparing a compound (I) according to claim 1 or 2, wherein the enol esterification reaction in the step (A) is an enol esterification reaction with an electrophile, an alkali metal salt, a base, and the compound represented by formula (1) .4.The method for preparing a compound (I) according to claim 1 or 2, wherein the methylation reaction in the step (B) is a methylation reaction with a methyl metal reagent, an additive, a metal catalyst, and the compound represented by formula (2) .5.The method for preparing a compound (I) according to claim 1 or 2, wherein the asymmetric hydrogen transfer reaction in the step (C) is an asymmetric hydrogen transfer reaction with a ligand, a metal, a reducing agent, and the compound represented by formula (3) .6.The method for preparing a compound (I) according to claim 5, wherein the ligand in the step (C) is (R) -1- [ (Sp) -2- (diphenylphosphino) ferrocenyl] ethyl di-tert-butylphosphine, the metal is copper (II) acetate monohydrate, and the reducing agent is triethoxysilane.7.The method for preparing a compound (I) according to claim 2, wherein the deprotection reaction in the step (D) is a deprotection reaction with a base and the compound represented by formula (4) .8.The method for preparing a compound (I) according to claim 2, wherein the carboxyl group activating agent in the step (E) is an acid anhydride.9.The method for preparing a compound (I) according to claim 2, wherein the deprotection reaction in the step (H) is a deprotection reaction with an acid, a base, and the compound represented by formula (8) .10.The method for preparing a compound (I) according to claim 2, further comprising:a step (K) of using the compound (II) and a compound represented by formula (9) :wherein R4 represents chlorine, bromine, iodine,and an arrow represents a bonding position with a carbon atom, and performing a nucleophilic substitution reaction to provide a compound (III) :wherein all symbols represent the same meaning as in claim 1 or 2;a step (M) of using the compound (III) and a compound represented by formula (10) :wherein R3 represents a C1 to C6 alkyl group or a benzyl group, and performing a reductive amination reaction to provide a compound represented by formula (11) :wherein all symbols represent the same meaning as in claim 1 or 2 and described above; anda step (P) of using the compound represented by formula (11) in a presence of 4-hydroxybenzoic acid and performing a deprotection reaction and adduct formation to provide a compound represented by formula (12) :wherein Y represents a number of 0 to 5 and other symbols represent the same meaning as in claim 1 or 2.11.The method for preparing a compound (I) according to claim 10, wherein the nucleophilic substitution reaction in the step (K) is a nucleophilic substitution reaction with a base, the compound represented by formula (9) , and the compound (II) .12.The method for preparing a compound (I) according to claim 10, wherein the reductive amination reaction in the step (M) is a reductive amination reaction with a reducing agent, an acid, the compound represented by formula (10) , and the compound (III) .13.The method for preparing a compound (I) according to claim 10, wherein the deprotection reaction in the step (P) is a deprotection reaction with a base.14.The method for preparing a compound (I) according to claim 10, further comprising:a step (R) of using the compound represented by formula (12) in the presence or absence of 4-hydroxybenzoic acid and performing crystal polymorph transition to provide the compound (I) .15.Ethyl (2Z) -4- (3-methoxyphenyl) -3- [ (4-methylbenzene-1-sulfonyl) oxy] but-2-enoate.
Citation Information
Patent Citations
Compound having s1p5 receptor agonist activity
WO2019163917A1
Salt and crystal form of compound having agonistic activity to s1p5 receptor
WO2021033729A1
Dihydronaphthalene derivative
EP3228615A1
Salt and crystal form of compound having agonistic activity to s1p5 receptor
EP4019496A1